United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3)] previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5)]. hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2)]. pregnancy category d. see ‘warnings and precautions’ section. epirubicin hydrochloride can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during days 5 to 1

United States - English - NLM (National Library of Medicine)

impax generics - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3)] previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5)]. hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2)]. teratogenic effects pregnancy category d. see ‘warnings and precautions’ section. epirubicin hydrochloride injection can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area bas

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3)]. previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5)] . hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2)]. pregnancy category d. see ‘warnings and precautions' section. epirubicin hydrochloride injection can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during days 5

United States - English - NLM (National Library of Medicine)

sandoz inc - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1) ]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3) ] previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5) ]. hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2) ]. pregnancy category d. see ‘warnings and precautions ’ section. epirubicin hydrochloride injection can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during

United States - English - NLM (National Library of Medicine)

generamedix, inc. - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - injection, solution - 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: baseline neutrophil count < 1500 cells/mm3 ; severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose; hypersensitivity to epirubicin, other anthracyclines, or anthracenediones; or severe hepatic dysfunction (see warnings and dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 20 mg - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

United States - English - NLM (National Library of Medicine)

otn generics inc. - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - injection, solution - 2 mg in 1 ml - epirubicin injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. patients should not be treated with epirubicin injection if they have any of the following conditions: baseline neutrophil count < 1500 cells/mm3 ; severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose; hypersensitivity to epirubicin, other anthracyclines, or anthracenediones; or severe hepatic dysfunction (see warnings and dosage and administration).